Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Sarcopenia, characterized by loss of skeletal muscle mass, quality, and strength, has become a common hallmark of ageing and many chronic diseases. Diabetes mellitus patients have a higher prevalence of sarcopenia, which greatly aggravates the metabolic disturbance and compromises treatment response. Preclinical and clinical studies have shown differential impacts of anti‐diabetic drugs on skeletal muscle mass, strength, and performance, highlighting the importance of rational therapeutic regimen from the perspective of sarcopenia risk. In this review, we provide an update on the regulation of muscle mass and quality by major anti‐diabetic drugs, focusing primarily on emerging data from clinical studies. We also discuss the underlying mechanisms and clinical implications for optimal selection of anti‐diabetic drugs to reduce the risk of sarcopenia. In view of the lifelong use of anti‐diabetic drugs, we propose that a better understanding of the sarcopenia risk and interventional strategies is worthy of attention in future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867 · cited 1×
“Some other studies have also shown that the use of SGLT2 inhibitors in T2DM patients reduces FM by two-thirds and lean mass by one-third.(78,79) Typically, both ipragliflozin and canagliflozin reduce the weight of FM and lean mass.”
ResultMusi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2074 · Cited by 806
Excessive Loss of Skeletal Muscle Mass in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Lee, J. S., Kuller, L. H., Boudreau, R., de Rekeneire, N., Harris, T. B., Kritchevsky, S., Tylavsky, F. A., Nevitt, M., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0264 · Cited by 778 · cited 2×
“Older people with diabetes are twice more likely to develop sarcopenia than those without diabetes.(6,7) The strength and resistance of skeletal muscle decreased significantly in type 2 diabetes mellitus (T2DM) patients.”
BackgroundAccelerated Loss of Skeletal Muscle Strength in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Strotmeyer, E. S., Kuller, L. H., Broudeau, R., Kammerer, C., de Rekeneire, N., Harris, T. B., Schwartz, A. V., Tylavsky, F. A., et al. (2007) · Diabetes Care · doi:10.2337/dc06-2537 · Cited by 766 · cited 1×
“Older people with diabetes are twice more likely to develop sarcopenia than those without diabetes.(6,7) The strength and resistance of skeletal muscle decreased significantly in type 2 diabetes mellitus (T2DM) patients.”
BackgroundDecreased Muscle Strength and Quality in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Strotmeyer, E. S., de Rekeneire, N., Harris, T. B., Schwartz, A. V., Tylavsky, F. A., & Newman, A. B. (2006) · Diabetes · doi:10.2337/db05-1183 · Cited by 751 · cited 1×
“The strength and resistance of skeletal muscle decreased significantly in type 2 diabetes mellitus (T2DM) patients.(8,9) Poor glycaemic control in patients with diabetes could further lead to low muscle mass.”
BackgroundUnderstanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686 · cited 1×
“liver, intestine, adipose tissue, as well as the muscle.(36) The glycaemic decrease during metformin treatment is more often accompanied by weight loss, and many studies have consistently associated long-term metformin use with decreased FM.”
BackgroundFunction and mechanisms of enteroendocrine cells and gut hormones in metabolism
Gribble, F. M., & Reimann, F. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0168-8 · Cited by 670
Sarcopenic obesity: a critical appraisal of the current evidence
Prado, C. M. M., Wells, J. C. K., Smith, S. R., Stephan, B. C. M., & Siervo, M. (2012) · Clinical Nutrition · doi:10.1016/j.clnu.2012.06.010 · Cited by 589
Prevalence and Determinant Factors of Sarcopenia in Patients With Type 2 Diabetes
Kim, T. N., Park, M. S., Yang, S. J., Yoo, H. J., Kang, H. J., Song, W., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., et al. (2010) · Diabetes Care · doi:10.2337/dc09-2310 · Cited by 585
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
Role of muscle mass and muscle quality in the association between diabetes and gait speed
Volpato, S., Bianchi, L., Lauretani, F., Lauretani, F., Bandinelli, S., Guralnik, J. M., Zuliani, G., & Ferrucci, L. (2012) · Diabetes Care · doi:10.2337/dc11-2202 · Cited by 294
Metformin as an Anticancer Agent
Vancura, A., Bu, P., Bhagwat, M., Zeng, J., & Vancurova, I. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.07.006 · Cited by 274
Insulin sensitizers may attenuate lean mass loss in older men with diabetes
Lee, C. G., Boyko, E. J., Barrett-Connor, E., Miljkovic, I., Hoffman, A. R., Everson-Rose, S. A., Lewis, C. E., Cawthon, P. M., Strotmeyer, E. S., Orwoll, E. S., et al. (2011) · Diabetes Care · doi:10.2337/dc11-1032 · Cited by 168 · cited 2×
“reported that TZD may reduce the loss of muscle mass in patients with impaired fasting glucose or diabetes.(41) However, the ACT NOW trial has shown that the lean body mass in the legs was significantly lower after 33.”
BackgroundAbbatecola, A. M., Paolisso, G., Fattoretti, P., Evans, W. J., Fiore, V., Dicioccio, L., & Lattanzio, F. (2011) · The Journal of nutrition, health and aging · doi:10.1007/s12603-011-0366-0 · Cited by 137
Colleluori, G., Aguirre, L., Phadnis, U., Fowler, K., Armamento-Villareal, R., Sun, Z., Brunetti, L., Hyoung Park, J., Kaipparettu, B. A., Putluri, N., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.008 · Cited by 135 · cited 1×
“In consistence, in obese elderly, combined aerobic and resistance exercise for 6 months is superior to improve muscle protein synthesis and myocellular quality, thereby maintaining muscle mass during weight-loss therapy.(95)”
BackgroundPerna, S., Guido, D., Bologna, C., Solerte, S. B., Guerriero, F., Isu, A., & Rondanelli, M. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-015-0525-y · Cited by 125 · cited 1×
“After 24 weeks of treatment, it was found that the reduction of body weight was mainly due to the decrease of FM, and liraglutide could prevent the degradation of muscle protein and maintain the stability of skeletal muscle.(62) However, in another study involving 21 T2DM patients undergoing haemodialysis, addition of…”
ResultCellular and molecular mechanisms of sarcopenia: The S100B perspective
Riuzzi, F., Sorci, G., Arcuri, C., Giambanco, I., Bellezza, I., Minelli, A., & Donato, R. (2018) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12363 · Cited by 114
Naznin, F., Sakoda, H., Okada, T., Tsubouchi, H., Waise, T. M. Z., Arakawa, K., & Nakazato, M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.028 · Cited by 114 · cited 1×
“found that treatment with canagliflozin for 8 weeks could induce body weight loss in mice, characterized by decreased mass of visceral and subcutaneous fat.(85) Despite these findings, there are still concerns that SGLT2 inhibitors may lead to muscle and bone mass loss, osteoporosis, and decreased body function.”
BackgroundLundkvist, P., Sjöström, C. D., Amini, S., Pereira, M. J., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12779 · Cited by 108
Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus
Ida, S., Kaneko, R., Imataka, K., Okubo, K., Shirakura, Y., Azuma, K., Fujiwara, R., & Murata, K. (2021) · Current Diabetes Reviews · doi:10.2174/1573399816666200705210006 · Cited by 85 · cited 1×
“A recent meta-analysis of randomized controlled trials also indicated that semaglutide was associated with both weight loss and FFM decrease, prompting the need to understand drug-specific effects on sarcopenic parameters.(64)”
Insulin Treatment Attenuates Decline of Muscle Mass in Japanese Patients with Type 2 Diabetes
Bouchi, R., Fukuda, T., Takeuchi, T., Nakano, Y., Murakami, M., Minami, I., Izumiyama, H., Hashimoto, K., Yoshimoto, T., & Ogawa, Y. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0251-x · Cited by 64
Mele, A., Calzolaro, S., Cannone, G., Cetrone, M., Conte, D., & Tricarico, D. (2014) · Pharmacology Research & Perspectives · doi:10.1002/prp2.28 · Cited by 58
Ferrari, U., Then, C., Rottenkolber, M., Selte, C., Seissler, J., Conzade, R., Linkohr, B., Peters, A., Drey, M., & Thorand, B. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01523-7 · Cited by 52 · cited 1×
“More recently, a longitudinal study of insulin therapy with changes in muscle parameters showed that insulin preserved muscle mass, but not muscle function as assessed by hand grip strength.(25) However, it is noteworthy that several early clinical studies examining insulin therapy and body composition have shown that…”
BackgroundShea, M. K., Nicklas, B. J., Marsh, A. P., Houston, D. K., Miller, G. D., Isom, S., Miller, M. E., Carr, J. J., Lyles, M. F., Harris, T. B., et al. (2011) · Obesity · doi:10.1038/oby.2010.327 · Cited by 49
The KATP channel is a molecular sensor of atrophy in skeletal muscle
Tricarico, D., Mele, A., Camerino, G. M., Bottinelli, R., Brocca, L., Frigeri, A., Svelto, M., George Jr, A. L., & Camerino, D. C. (2010) · The Journal of Physiology · doi:10.1113/jphysiol.2009.185835 · Cited by 49 · cited 2×
“Furthermore, glibenclamide was found to enhance caspase-3 activity in slow-twitch muscle and reduce the ratio of protein concentration to muscle weight.(31) Given the intimate relationship between KATP channel and skeletal muscle homeostasis, the suppressive effect of sulfonylureas and glinides on the KATP channel rai…”
BackgroundMarsh, A. P., Kyla Shea, M., Vance Locke, R. M., Miller, M. E., Isom, S., Miller, G. D., Nicklas, B. J., Lyles, M. F., Carr, J. J., & Kritchevsky, S. B. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/gls258 · Cited by 36
Wang, G., Wu, P., Qiu, Y., Dong, X., Wang, Y., Chi, Y., Zhang, F., Li, Y., Zhang, J., Huang, Z., et al. (2021) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000388 · Cited by 17 · cited 1×
“Several studies have reported that GLP-1 or GLP-1 analogues can cause weight loss in animals and humans.(53,54) The mechanisms are likely attributed to decreased energy intake (e.”
Background
Cited by
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358
Higher Risk of Sarcopenia in Older Adults with Type 2 Diabetes: NHANES 1999–2018
Dai, S., Shu, D., Meng, F., Chen, Y., Wang, J., Liu, X., Xiao, X., Guo, W., & Chen, F. (2023) · Obesity Facts · doi:10.1159/000530241 · Cited by 63
Giannakogeorgou, A., & Roden, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17848 · Cited by 30
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101681 · Cited by 30
Metadata
- Authors
- Zhang, X., Zhao, Y., Chen, S., & Shao, H.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2021-10-21
- Volume
- 12
- Issue
- 6
- Pages
- 1368-1379
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W3207613937
- Cited by
- 92
- References
- 27
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.